Get started
Protalix BioTherapeutics, Inc. (DE)Protalix BioTherapeutics, Inc. (DE)Protalix BioTherapeutics, Inc. (DE)

Protalix BioTherapeutics, Inc. (DE)

No trades
OverviewFinancialsNewsDocumentsIdeasMindsTechnicalsForecastsSeasonalsOptionsETFs

Market insights

Tomorrow may tell..As most of us know this stock doesn't deal well with resistance !! So..after poking through support I really have no idea what will happen tomorrow. I am invested in this and like many cant seem to understand why this stock has such weak abilities. Hopefully... it draws some buyers here soon and can rise above support. But it may just keep dipping lower till closer to Jan 26th. I believe thats the date. Anyone who has held this for yrs... myself included. Lets try and gather our strength and hold out for at least 8.49!! Sigh
AMEX:PLX
by DeeAngela
$PLX - Turtle progress (Today's announcement - read below)CARMIEL, Israel, August 24, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced completion of the treatment period of its Phase III BRIGHT clinical trial of pegunigalsidase alfa, or PRX-102, for the proposed treatment of Fabry disease. The Company is currently working with its service providers to complete the final monitoring visits necessary for final analysis of the data; however, many sites are still impacted by ongoing local and state restrictions and precautions due to the COVID-19 pandemic. The Company anticipates announcing top-line results in the fourth quarter of 2020 once this process is completed. “Completion of the BRIGHT study marks another important key milestone in our pursuit of an alternative dose and regimen of pegunigalsidase alfa for the proposed treatment of Fabry disease,” said Dror Bashan, President and Chief Executive Officer of Protalix BioTherapeutics. “We eagerly anticipate announcement of top-line data, and are working towards the completion of the final monitoring visits as quickly as possible. Our challenge now is to continue the work to finalize these last details with the ongoing headwinds from COVID-19. I am very proud of our team’s execution in completing the study and am confident in their ability to have the final data as expeditiously as possible.” Mr. Bashan continued, “The BRIGHT study is the second Phase III study of PRX-102 in Fabry patients that we have completed as part of our comprehensive PRX-102 development program. We announced positive results earlier this year from our Phase III BRIDGE clinical trial, and we anticipate results from an interim analysis of our Phase III BALANCE clinical trial in the first half of 2021. In addition, earlier this month, we announced the filing of the PRX-102 BLA by the U.S. Food and Drug Administration with a PDUFA target date of January 27, 2021.” Very Risky stock Not for any advise
AMEX:PLX
by Samuel12_1980